Two Biotechs I liked in 2016: Medivation and Portage Biotech

“Those who have knowledge, don’t predict. Those who predict, don’t have knowledge.” –  Lao Tzu, 6th Century BC Chinese Poet

In 2016 I made mention publicly of only two equities that I really liked, Medivation and Portage Biotech.

Medivation I started to Tweet about in early April 2016 (see screenshot below) as a good candidate to be taken over by the end of the year. The stock at the time was trading around $40US. I had an aggressive target of $80. Just 100 days later, Pfizer said it had agreed to buy Medivation Inc. for $81.50 a share, valuing the total company at about $14 billion.

Portage Biotech is a penny stock that trades on the OTCBB at around .13c. ($PTGEF)

Many of the same players that built Medivation from a penny stock microcap to a $14 billion market cap takeover in 12 years are involved in Portage Biotech. A few weeks ago, Portage subsidiary company Biohaven completed a financing for $80 Million.

With Medivation now merged, Portage continues to be a favorite heading into 2017.

I look forward to finding you some more gems as soon as we uncover them.

Happy investing,

Anna Morera Leralta

Anna Morera Leralta

Medical Doctor specializing in Integrative Medicine and exploring the Medical Cannabis opportunity. Also fascinated by the convergence of Life Sciences and Technology - in particular Artificial Intelligence and how it will affect health care in the future. During my internships and volunteering, I have worked hand-in-hand with well-know physicians and professionals of the Health-Biotech sector. I've been awarded with numerous awards of excellence and scholastic scholarships. I'm a co-founder of an IoT startup that aims to help smokers successfully quit. Born and raised in Barcelona - Spain, with a zest for traveling, learning and expanding my horizons. Always curious, hard-working, open-minded and self-motivated.

No Comments Yet

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Subscribe to the IBR blog

Keep up to date with our latest news and recommendations by getting them straight to your inbox!

We will never spam you or give your email address to a third party.